Phase 3 N=392 Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
Dementia-related Psychosis
Primary: Time From Randomization to Relapse in the Double-blind (DB) Period — NA; NA days — p=0.0023
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=21 Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants
Pulmonary Arterial Hypertension
Primary: Geometric Mean Ratio of Dose Normalized Area Under the Curve From Time Zero to Tau (AUCtau) for Bosentan Before and After Imatinib Administrations — 93.3; 109; 131…
Phase 3 N=399 Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 (Sotagliflozin 400 mg Versus Placebo) — -0.34; -1.03 percentage of HbA1c — p=<0.0001
Phase 3 N=1,351 Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
Infections, Rotavirus
Primary: Number of Subjects With Any Solicited General Adverse Events (AEs) After the First Vaccination — 139; 166; 41; 47 Participants
Phase 3 N=234 Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection
Gastric Ulcer
Primary: Percentage of Participants With Endoscopically Confirmed Healing of Gastric Ulcers (GUs) at Weeks 4 or 8 — 91.1; 94.7 percentage of participants
Phase 3 N=308 Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD
ADHD
Primary: Efficacy of SPN-812 Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale, 5th Edition (ADHD-RS-5) — -11.4; -16.0; -16.5 units on a scale — p=0.0232
Phase 3 N=773 A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis
Axial Spondyloarthritis
Primary: Percentage of Participants Who do Not Experience a Flare (Combined Ixekizumab Treatment) — 83.3; 54.7 Percentage of participants — p=<0.001
Phase 3 N=72 A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin
Heart Failure
Primary: Change From Baseline to Week 12 in PCr/ATP Ratio in the Resting State Measured by 31P Cardiac Magnetic Resonance Spectroscopy (MRS). — 0.068; 0.259; -0.179; 0.100 PCr /…
Phase 3 N=1,176 Study Comparing a Generic Diclofenac Sodium Topical Gel, 1% to Voltaren in the Treatment of Subjects With Osteoarthritis of the Knee
Osteoarthritis
Primary: Change From Baseline to 4 Weeks in WOMAC Pain Score — 2.2332; 2.0287; -0.6387 score on a scale
Phase 3 N=104 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)
Pneumococcal Infections
Primary: Percentage of Participants With a Solicited Injection-site Adverse Event — 4.3; 5.9; 8.7; 8.8 Percentage of participants
Phase 3 N=732 A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027)
Chronic Cough
Primary: Model-Based Geometric Mean Ratio (GMR) of 24-hour Objective Coughs Per Hour (Week 12/Baseline) — 0.47; 0.48; 0.38 ratio — p=0.041
Phase 3 N=357 Aurinia Renal Response in Active Lupus With Voclosporin
Lupus Nephritis
Primary: Number of Participants With Adjudicated Renal Response at Week 52 — 73; 40; 106; 138 Participants — p=<0.001
Phase 3 N=38 Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis
Uveitis · Uveitis, Posterior · Uveitis, Anterior
Primary: Adverse Events — 27; 1 Participants
Phase 3 N=533 Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
Melanoma
Primary: Incidence of Participants With High-Grade (CTCAE v4.0 Grade 3-5) Treatment-Related Select Adverse Events — 7; 7; 0; 0 Participants
Phase 3 N=744 Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine
Episodic Migraine
Primary: Percentage of Participants With at Least 1 Treatment Emergent Adverse Event (TEAE) — 78.6; 67.0 percentage of participants